Genmab A/S ADS (GMAB)
NASDAQ: GMABHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 36.65 0.00%
GMAB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $22.54B
- P/E (TTM)
- 29.56
- Forward P/E
- 24.03
- EPS (TTM)
- $1.24
- Dividend yield
- None
- 52-week range
- 23.62 – 40.17
- Day range
- 36.27 – 37.86
- Volume / Avg
- 4.25M / 2.78M
- Beta
- —
- Shares outstanding
- 614.90M
- Next earnings
- Nov 5, 2026
52-week range
GMAB stock today
Genmab A/S (GMAB) closed at $36.65 on Oct 7, down 3.04% (-$1.15), versus the S&P 500's 0.22% decline. Shares are 8.8% below their 52-week high of $40.17, set on Oct 5, 2026 and 55.2% above the 52-week low of $23.62, in the middle of the past year's range. GMAB is up 19.0% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 12.3%.
Genmab A/S trades at 29.6x its trailing twelve-month earnings per share of $1.24. Its forward P/E of 24.0x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Genmab A/S's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Genmab A/S
Company profileGenmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Jan G.J. van de Winkel Ph.D.
- Headquarters
- Copenhagen
- Employees
- 3,119
- IPO year
- 2019
- Website
- genmab.com
Financial highlights
Full financialsIn fiscal 2025, Genmab A/S generated $3.72 billion in revenue, up 19.2% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $963.0 million (-15.0% year over year), for a net margin of 25.9% versus a median of 31.4% in the prior 2 years. Gross margin was 93.6% (down from 95.4%) and operating margin 28.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $3.72B | $3.12B | $2.39B |
| Growth | +19.19% | +30.59% | — |
| Net income | $963.00M | $1.13B | $631.00M |
| EPS (diluted) | $15.37 | $17.53 | $9.58 |
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$43.22+17.93%
- Strong buy 1
- Buy 10
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $0.37
GMAB news
All GMAB newsGenmab A/S peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ERASErasca Inc. | 14.12 | -1.26% | $4.94B | vs GMAB |
| DNTHDianthus Therapeutics Inc. | 84.88 | -0.61% | $4.75B | vs GMAB |
| TVTXTravere Therapeutics Inc. | 53.44 | -4.54% | $5.04B | vs GMAB |
| MANEVeradermics Incorporated | 110.95 | +1.83% | $4.64B | vs GMAB |
| GRFSGrifols S.A. ADR | 7.50 | -0.27% | $5.10B | vs GMAB |
| COGTCogent Biosciences Inc. | 30.14 | -0.79% | $5.23B | vs GMAB |
| MIRMMirum Pharmaceuticals Inc. | 80.64 | +1.75% | $5.24B | vs GMAB |
| PTCTPTC Therapeutics Inc. | 63.23 | -0.74% | $5.28B | vs GMAB |
Indexes, lists and sector
Genmab A/S stock FAQ
What is Genmab A/S's stock price today?
GMAB last traded at $36.65 as of Oct 7, 4:00 PM EDT, down 3.04% on the day. Prices are delayed at least 15 minutes.
Does Genmab A/S pay a dividend?
No. Genmab A/S does not currently pay a regular cash dividend.
When is Genmab A/S's next earnings date?
Genmab A/S is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $0.37.
What is GMAB's P/E ratio?
GMAB trades at a trailing P/E ratio of 29.56 and a forward P/E of 24.03.
Who is Genmab A/S's CEO?
Dr. Jan G.J. van de Winkel Ph.D. is the chief executive officer of Genmab A/S ADS, which has about 3,119 employees.
Has GMAB ever split its stock?
Yes. The most recent GMAB stock split was a 5-for-1 split on May 1, 2018.
What is the GMAB 52-week high?
The 52-week high for GMAB is $40.17 and the 52-week low is $23.62. The stock is currently 8.8% below its high.